



ORIGINAL PAPER

Relationships between comorbidities and vitamin D intake with COVID-19 severity

Muhammad Rifky¹, Verawati Sudarma^{2,3}

Received 30 January 2026
Accepted 9 April 2026
Published 31 August 2026

Link to DOI:

[10.25220/WNJ.V10.i1.0002](https://doi.org/10.25220/WNJ.V10.i1.0002)

Citation: Rifky M, Sudarma V. Relationships between comorbidities and vitamin D intake with COVID-19 severity. World Nutrition Journal. 2026 August 31;10(i1): 11-18.



Copyright: © 2026 by the authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).
<http://www.worldnutrijournal.org>

1. Medical Education Study Program, Faculty of Medicine, Universitas Trisakti
2. Department of Nutrition, Faculty of Medicine, Universitas Trisakti
3. Center for Nutritional Studies, Universitas Trisakti

Abstract

Background: Vitamin D is a nutrient/hormone-like vitamin involved in immune regulation, which, in turn, affects morbidity and mortality rates, including in coronavirus disease 2019 (COVID-19). Vitamin D strengthens both specific and nonspecific immunity and modulates the body's response to infection.

Objective: This study aims to determine the association between comorbidities and vitamin D intake with the severity of COVID-19.

Methods: The study is a cross-sectional observational study with a sample comprised of 66 people, ages 19 to 58, receiving treatment for COVID-19 at Pasar Rebo District Hospital. The primary data were collected via a questionnaire administered via the WhatsApp application or through direct interviews, encompassing variables such as age, gender, comorbidity, and vitamin D intake. The Vitamin D Dietary Intake Questionnaire was conducted using the Food Frequency Questionnaire (FFQ). Vitamin D intake is categorized into two groups: low (<600 IU/day) and adequate (≥600-4,000 IU/day). Comorbidities are other illnesses that a person has, such as asthma, high blood pressure, diabetes, or heart disease. The severity of COVID-19 is in accordance with the criteria set by the Indonesian Society of Internal Medicine. Statistical analysis used SPSS version 22 to analyze univariate data and Fisher's exact test for bivariate analysis with a significance limit of $p < 0.05$.

Results: A total of 25.8% of the subjects had comorbidities, 62.1% experienced low vitamin D intake, and 53% experienced mild COVID-19 symptoms. The severity of COVID-19 cases does not correlate with age or gender. The severity of COVID-19 cases was significantly associated with comorbidities ($p=0.001$) and vitamin D intake ($p=0.021$).

Conclusion: An association was observed between vitamin D intake, comorbidities, and the severity of COVID-19.

Keywords: vitamin D, COVID-19, comorbidities

Corresponding author:

Verawati Sudarma
Department of Nutrition, Faculty of
Medicine, Universitas Trisakti, Jakarta,
Indonesia
verasudarma@trisakti.ac.id



Introduction

The World Health Organization has declared an international emergency due to the devastation caused by the COVID-19 epidemic.¹ An RNA virus, known as a coronavirus, carries small particles and can spread through droplets. The infection mainly occurs in animals, but currently, transmission is primarily human-to-human, and the spread is very aggressive.² Many factors, including the host, virus, and environment, can influence COVID-19 severity. Age can influence the severity of different cases.³ Diet is another independent risk factor for developing serious infections. It is critical to consume healthy, fresh, and nutritious foods while avoiding diets high in saturated fats, sugar, and refined carbohydrates. Vitamin D deficiency may influence comorbidities and susceptibility to infectious disease.³

The immune system of the body greatly influences an individual's susceptibility, morbidity, and mortality from COVID-19, as with other viral diseases. One factor that can influence the body's immune response is vitamin D.⁴ Vitamin D can reduce the risk of viral infection through a number of approaches, including strengthening both specific and nonspecific immunity and modulating the body's response to an infection. Vitamin D also plays a role in adaptive and innate immune responses, which are essential for inhibiting cytokine storms and reducing pro-inflammation responses.^{4,5} Vitamin D deficiency has been hypothesized contributes to the occurrence of acute respiratory distress syndrome (ARDS) (SARS-CoV-2).⁵ As previously explained, the objective of this study was to determine whether vitamin D intake and comorbidities were associated with COVID-19 severity.

Methods

This is an analytical observational study with a cross-sectional design. The research was conducted at Pasar Rebo District Hospital from November to December 2021. The research sample came from the medical records of 66 subjects inpatients aged 19-58 years diagnosed with COVID-19 who met the inclusion criteria. The inclusion criteria are as follows: patients diagnosed with COVID-19 by PCR test. The exclusion criteria are patients who are still under treatment in the hospital and patients who died during treatment. Primary data were collected through a questionnaire completed via the WhatsApp application, which included age, gender, and vitamin D intake, while comorbidities and COVID-19 severity were taken from medical records. Direct interviews are conducted when WhatsApp responses are unclear. Comorbidities are accompanying illnesses (asthma, hypertension, diabetes, heart disease) that describe the patient's condition apart from the primary illness, namely COVID-19, recorded in the medical record; "yes" indicates one or more comorbidities. The vitamin D dietary intake questionnaire was conducted using the Food Frequency Questionnaire (FFQ) past month. The vitamin D intake is categorized into two groups based on the Minister of Health Regulation Number 28 of 2019 concerning Nutritional Adequacy Rates; low (<600 IU/day) and adequate (≥ 600 - 4,000 IU/day). The severity of COVID-19 is an accordance with the criteria set by the Indonesian Society of Internal Medicine.⁶ The severity of COVID-19 is determined by the patient's worst condition during hospital treatment.

To process and analyze the data, the Statistical Package for the Social Sciences (SPSS) 22.0 was used. Categorical variables were expressed as frequencies and percentages. Intergroup comparison was conducted using Fisher's exact test because the expected



count of less than 5 is more than 20%. To determine statistical significance, a p-value of less than 0.05 was used. Multivariate analysis was not considered due to insufficient data.

Results

The Research Ethics Commission of Universitas Trisakti, with number 104/KER-FK/IX/2021, declared this research to have passed the ethical test. After processing and counting the respondents, we analyzed 66 subjects, yielding a response rate of 100%. No data was missing or excluded from the analysis.

Table 1. Subject characteristics (N = 66)

Variables	Frequencies	
	N	(%)
Age		
19 – 48 years old	49	74.2
49 – 58 years old	17	25.8
Sex		
Men	36	54.5
Women	30	45.5
Comorbidities		
Yes	17	25.8
No	49	74.2
Vitamin D intakes		
Low	41	62.1
Adequate	25	37.9
Severity of COVID-19 cases		
Asymptomatic	10	15.2
Mild	35	53
Moderate	3	4.5
Severe	12	18.2
Critical	6	9.1

Table 1 displays the characteristics of the largest age group, the 19-48-year-olds, who account for 74.2% of the subjects. Most subjects were male (54.5%), and 74.2% of research subjects did not have comorbidities. The group with the highest vitamin D intake was the one with an insufficient intake, accounting for 62.1%. The most severe category of COVID-19 cases is the mild group, at 53%.

In **Table 2**, according to statistical tests, there was no significant association between age ($p=0.064$) and gender ($p=0.791$) and the severity of COVID-19 cases. Subjects with comorbidities had higher COVID-19 severity, this trend was evident in the statistical analysis, which showed a significant association ($p=0.001$). The group with the lowest vitamin D intake experienced the mildest symptoms of COVID-19, where the analysis showed a significant association between vitamin D intake and COVID-19 severity ($p=0.021$).

**Table 2.** Characteristics of subjects and vitamin D intake with severe COVID-19 cases

Variables	Severity of COVID-19										p-value
	Asymptomatic	%	Mild	%	Moderate	%	Severe	%	Critical	%	
Age											
19 – 48 y.o	9	18.4	26	53.1	0	0	9	18.4	5	10.2	0.064
49 – 58 y.o	1	5.9	9	52.9	3	17.6	3	17.6	1	5.9	
Sex											
Men	7	19.4	19	52.8	2	5.6	5	13.9	3	8.3	0.791
Women	3	10	16	53.3	1	3.3	7	23.3	3	10	
Comorbidities											
Yes	0	0	3	17.6	2	11.8	6	35.3	6	35.3	0.001*
No	10	20.4	32	65.3	1	2	6	12.2	0	0	
Vitamin D intakes											
Low	2	4.9	26	63.4	1	2.4	8	19.5	4	9.8	0.021*
Adequate	8	32	9	36	2	8	4	16	2	8	

Fisher's exact test; *p<0.05

Discussion

The largest group of subjects aged 19 – 48 years was 74.2%; this is also the same as the percentage of subjects with no comorbidities. Several factors can contribute to the high percentage of non-comorbidities in the 19-48-year-old group. Diabetes is typically diagnosed at age ≥ 40 years⁷⁻⁹, as well as several reports, show that the presence of early-onset hypertension (onset at age ≤ 55 years) is lower¹⁰.

Indonesia is a tropical country, yet many of its citizens have low vitamin D levels because they tend to avoid direct sunlight and don't eat enough vitamin D-rich foods. Fish oil, liver, and seafish like mackerel, salmon, sardines, and tuna are high sources of vitamin D.¹¹ In addition, vitamin D fortifies many foods, particularly dairy products and cereals.¹¹ However, in Indonesia, vitamin D intake is generally obtained from eggs and freshwater fish rather than seafish.¹² The FFQ used to analyze vitamin D intake included both dietary vitamin D and supplement use. Unfortunately, this questionnaire did not ask about sun exposure, leaving it unmeasured.

The body's immune system weakens with age, increasing the likelihood of infection and making it more challenging for individuals of that age to combat infections.¹³ Based on statistical tests, there is no association between age and the severity of COVID-19 cases ($p = 0.064$), similar to Betsy Szeto et al.,¹⁴ research. This also implies that individuals of all ages are susceptible to severe COVID-19. Younger children, who often have close contact with peers, can easily transmit the virus in school settings, while adults may spread it in workplaces or social gatherings. Older individuals, particularly in communal living environments, are at risk of rapid transmission due to shared spaces and activities. Even though it is risky, individuals can prevent it by following standard health protocols.¹⁵

Aging is linked to a variety of morbidities. As protective immunity deteriorates, older people become susceptible to infections and inflammatory diseases.¹⁶ Older people are far more likely to make autoantibodies.¹⁷ Essentially, immunological aging correlates with diminishing protective immunity alongside a rising prevalence of inflammatory



diseases. This, in turn, can lead to an increased risk of developing more serious illnesses. Therefore, it is important to take preventive measures to reduce the risk of age-related diseases. The absence of a correlation between age and COVID-19 severity may be due to the study participants' young age.

Different immunological responses to infection have at least partially contributed to the complexity of sex differences.¹⁸ Males have more frequently experienced severe outcomes and deaths from COVID-19 than females, according to several studies.¹⁹ Multivariate analysis, however, showed females experienced more severe systemic and total symptoms than males.²⁰ Numerous prior studies have assessed sex disparities in clinical outcomes among hospitalized or severely ill COVID-19 patients.²¹ In contrast to previous research, this study found no association between gender and COVID-19 case severity ($p = 0.753$).

The study results showed a significant association between comorbidities (asthma, hypertension, DM, heart disease) and COVID-19 severity ($p = 0.001$). Felly Philipus Senewe et al.,²² research revealed a significant relationship between comorbidities and COVID-19 cases (p -value = 0.001), indicating a correlation between the respondent's comorbidities and COVID-19 case severity. Comorbidities can influence COVID-19 progression and cause more severe organ damage. For example, individuals who experience low-grade inflammation due to hypertension, diabetes mellitus, and chronic kidney disease can influence the severity of COVID-19 cases due to a systemic inflammatory process with multiorgan involvement.²³

The severity of COVID-19 cases was statistically significantly correlated with vitamin D intake ($p = 0.021$). The FFQ used in this study to analyze vitamin D intake includes data on intake from food and supplementation. Generally, the research discussed focuses on vitamin D intake from supplementation. Vitamin D supplementation helps lower the risk of death in Covid patients (OR: 0.48; 95% CI: 0.346–0.664; $p < 0.001$). Additionally, it was also observed that supplementation decreased the need for mechanical ventilation (OR: 0.54; 95% CI: 0.411–0.708; $p < 0.001$) and intensive care (OR: 0.35; 95% CI: 0.28–0.44; $p < 0.001$).²⁴

Another meta-analysis of nine studies involving 870 participants revealed that vitamin D intake was linked to a decreased risk of death (RR: 0.76; 95% CI 0.60–0.97).²⁵ Additionally, other meta-analyses demonstrated a favorable impact of vitamin D3 supplementation on ICU admission (RR: 0.73; 95% CI: 0.57–0.95; $p = 0.02$) and COVID-19-related patient mortality (RR: 0.56; 95% CI: 0.34–0.91; $p = 0.02$).²⁶ In contrast to earlier research, a meta-analysis of eight randomized clinical trials (RCTs) revealed that giving vitamin D to COVID-19 patients did not significantly alter morbidity (OR: 0.50, 95% CI: 0.13–1.96).²⁷

Vitamin D has different mechanisms for dealing with the risk of viral infections, such as COVID-19. COVID-19 has the hallmarks of a severe infection, namely a cytokine storm. Cytokine storms can trigger individual immune responses to inflammatory pathogens, leading to multiple organ failure and more severe cases of COVID-19.^{28,29} Vitamin D has immunomodulatory properties and increases innate cellular immunity by reducing cytokine storms induced by the innate immune system, thereby affecting the body's defenses. The innate immune system produces pro-inflammatory and anti-inflammatory cytokines in response to bacterial and viral infections. The innate immune system supports innate immunity by producing several antimicrobial peptides (cathelicidins, defensins, and IL-37). Additionally, vitamin D modulates the production



and release of proinflammatory cytokines like IL-6, TNF-alpha, and interferon-gamma and controls responses mediated by Th lymphocytes.³⁰

Vitamin D deficiency is linked with metabolic disorders, autoimmune diseases, and infections. Numerous research studies highlight the association between vitamin D deficiency and an elevated risk of respiratory tract infections. Furthermore, vitamin D deficiency is prevalent in critically ill patients and has been linked with more serious illnesses. The high number of severe COVID-19 patients with inadequate vitamin D levels suggests a link between low vitamin D levels and poor outcomes. Taking vitamin D might reduce the severity of the disease and increase the chances of recovery.²⁷

Limitations of this study include the lack of control for potential confounding factors. Two potentially important confounding factors are subjects' cycle threshold (CT) values and sun exposure. Excluding patients who died during treatment and analyzing comorbidities as a single group may introduce bias. It must also be understood that dietary intake may not reflect serum vitamin D status. This study is a cross-sectional study, which means it cannot establish causality and primarily supports hypothesis formation.

Conclusion

Comorbidities and vitamin D intake are associated with the severity of COVID-19 infection. It is recommended that the initial assessment of COVID-19 patients include identification of comorbidities. Further research on the impact of vitamin D intake, adjusting for confounding variables, may be necessary to minimize the severity of COVID-19.

Conflict of interest

The authors declared no conflict of interest regarding this article.

Acknowledgement

We would like to thank Pasar Rebo District Hospital for continuous support of this study.

Open Access

This article is distributed under the terms of the Creative Commons Attribution 4.0 International Licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Author Contributions

MR: Conceptualization, data acquisition, formal analysis, interpretation of results, drafting the manuscript, and final approval of the version to be published; VS: Conceptualization, supervision, critical revision of the manuscript, interpretation of data, and final approval of the version to be published.



References

1. Coronavirus disease (COVID-19) pandemic [Internet]. Available from: <https://www.who.int/europe/emergencies/situations/covid-19>
2. Grudlewska-Buda K, Wiktorczyk-Kapischke N, Wałęcka-Zacharska E, Kwiecińska-Piróg J, Buszko K, Leis K, et al. SARS-CoV-2—Morphology, Transmission and Diagnosis during Pandemic, Review with Element of Meta-Analysis. *J Clin Med*. 2021 May 3;10(9):1962. doi:10.3390/jcm10091962
3. Samadizadeh S, Masoudi M, Rastegar M, Salimi V, Shahbaz MB, Tahamtan A. COVID-19: Why does disease severity vary among individuals? *Respir Med*. 2021 Apr;180:106356. doi:10.1016/j.rmed.2021.106356
4. Wang X, Zhang Y, Fang F. Role of vitamin D in COVID-19 infections and deaths. *J Evid-Based Med*. 2021 Feb;14(1):5–6. doi:10.1111/jebm.12421
5. Grant W, Lahore H, McDonnell S, Baggerly C, French C, Aliano J, et al. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. *Nutrients*. 2020 Apr 2;12(4):988. doi:10.3390/nu12040988
6. Indonesian Society of Internal Medicine. Buku Pedoman Tatalaksana COVID-19 [Internet]. Available from: <https://www.papdi.or.id/download/1153-buku-pedoman-tatalaksana-covid-19-edisi-4-januari-2022>.
7. Wang M, He Y, He Q, Di F, Zou K, Wang W, et al. Comparison of clinical characteristics and disease burden between early- and late-onset type 2 diabetes patients: a population-based cohort study. *BMC Public Health*. 2023 Dec 4;23(1):2411. doi:10.1186/s12889-023-17280-5
8. Cha E, Pasquel FJ, Yan F, Jacobs DR, Dunbar SB, Umpierrez G, et al. Characteristics associated with early- vs. later-onset adult diabetes: The CARDIA study. *Diabetes Res Clin Pract*. 2021 Dec;182:109144. doi:10.1016/j.diabres.2021.109144
9. Cigolle CT, Blaum CS, Lyu C, Ha J, Kabeto M, Zhong J. Associations of Age at Diagnosis and Duration of Diabetes with Morbidity and Mortality Among Older Adults. *JAMA Netw Open*. 2022 Sep 30;5(9):e2232766. doi:10.1001/jamanetworkopen.2022.32766
10. Huo X, Gao L, Guo L, Xu W, Wang W, Zhi X, et al. Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study. *Lancet Diabetes Endocrinol*. 2016 Feb;4(2):115–24. doi:10.1016/S2213-8587(15)00508-2
11. Zgaga L, Theodoratou E, Farrington SM, Agakov F, Tenesa A, Walker M, et al. Diet, Environmental Factors, and Lifestyle Underlie the High Prevalence of Vitamin D Deficiency in Healthy Adults in Scotland, and Supplementation Reduces the Proportion That Are Severely Deficient. *J Nutr*. 2011 Aug;141(8):1535–42. doi:10.3945/jn.111.140012
12. Prihashinta AW, Putriana D. Asupan Vitamin D, Frekuensi Makan dan Keluhan Gejala Gastritis pada Mahasiswa. *J Nutr Coll*. 2022 Apr 28;11(2):120–5. doi:10.14710/jnc.v11i2.33126
13. Weyand CM, Goronzy JJ. Aging of the Immune System. Mechanisms and Therapeutic Targets. *Ann Am Thorac Soc*. 2016 Dec;13(Supplement_5):S422–8. doi:10.1513/AnnalsATS.201602-095AW
14. Szeto B, Zucker JE, LaSota ED, Rubin MR, Walker MD, Yin MT, et al. Vitamin D Status and COVID-19 Clinical Outcomes in Hospitalized Patients. *Endocr Res*. 2021 Apr 3;46(2):66–73. doi:10.1080/07435800.2020.1867162
15. Vermonte P, Wicaksono TY. Karakteristik dan Persebaran COVID-19 di Indonesia: Temuan Awal [Internet]. Available from: <https://csis.or.id/publication/karakteristik-dan-persebaran-covid-19-di-indonesia-temuan-awal/>
16. Bansilal S, Castellano JM, Fuster V. Global burden of CVD: focus on secondary prevention of cardiovascular disease. *Int J Cardiol*. 2015 Dec;201:S1–7. doi:10.1016/S0167-5273(15)31026-3
17. Hurme M, Korkki S, Lehtimäki T, Karhunen PJ, Jylhä M, Hervonen A, et al. Autoimmunity and longevity: Presence of antinuclear antibodies is not associated with the rate of



- inflammation or mortality in nonagenarians. *Mech Ageing Dev.* 2007 May;128(5–6):407–8. doi:10.1016/j.mad.2007.03.001
18. World Health Organization (WHO). Addressing sex and gender in epidemic-prone infectious diseases. 2007 [Internet]. Available from: https://apps.who.int/iris/bitstream/handle/10665/43644/9789241595346_eng.pdf
19. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. *Front Public Health.* 2020 Apr 29;8:152. doi:10.3389/fpubh.2020.00152
20. Massion SP, Howa AC, Zhu Y, Kim A, Halasa N, Chappell J, et al. Sex differences in COVID-19 symptom severity and trajectories among ambulatory adults. *Influenza Other Respir Viruses.* 2023 Dec;17(12):e13235. doi:10.1111/irv.13235
21. Klein SL, Dhakal S, Ursin RL, Deshpande S, Sandberg K, Mauvais-Jarvis F. Biological sex impacts COVID-19 outcomes. Coyne CB, editor. *PLOS Pathog.* 2020 Jun 22;16(6):e1008570. doi:10.1371/journal.ppat.1008570
22. Senewe FP, Pracoyo NE, Marina R, Letelay AM, Sulistiyowati N. Pengaruh Penyakit Penyerta/Komorbid dan Karakteristik Individu dengan Kejadian COVID-19 di Kota Bogor Tahun 2020. *J Ekol Kesehat.* 2021 Oct 18;20(2):69–79. doi:10.1371/journal.ppat.1008570
23. Karya KWS, Suwidnya IM, Wijaya BS. Hubungan penyakit komorbiditas terhadap derajat klinis COVID-19. *Intisari Sains Medis.* 2021 Aug 31;12(2):708–17. doi:10.15562/ism.v12i2.1143
24. Shah K, Varna VP, Sharma U, Mavalankar D. Does vitamin D supplementation reduce COVID-19 severity?: a systematic review. *QJM.* 2022 Oct 25;115(10):665–672. doi: 10.1093/qjmed/hcac040
25. Zhu L, Zhang Y, Li X, Zou X, Bing P, Qi M, He B. Vitamin D supplementation for managing COVID-19 in patients with vitamin D deficiency: a systematic review and meta-analysis of randomised controlled trials. *BMJ Open.* 2025 Mar 26;15(3):e091903. doi: 10.1136/bmjopen-2024-091903
26. Sobczak M & Pawliczak R. Effect of Vitamin D3 Supplementation on Severe COVID-19: A Meta-Analysis of Randomized Clinical Trials. *Nutrients* 2024;16(10):1402. <https://doi.org/10.3390/nu16101402>
27. Utami DM, Ash-Shiddiq MAR, Rahmadhani DR, Mubarak MI, Tasman MZ, Sibarani JN, Fauziyah HTA, Utomo B, Fauziyah S. Meta-Analysis optimal dose of vitamin for Covid-19 treatment. *Fol Med Indones, Vol.58 No. 4 December 2022:* 383–392. doi: 10.20473/fmi.v58i4.36474
28. Balqis FE. Peran Vitamin D pada Infeksi Covid-19. *J Penelit Perawat Prof.* 3(4):669–82.
29. Tian Y, Rong L. Letter: Covid-19, and vitamin D. Authors' reply. *Aliment Pharmacol Ther.* 2020 May;51(10):995–6. doi:10.1111/apt.15764
30. Chiodini I, Gatti D, Soranna D, Merlotti D, Mingiano C, Fassio A, et al. Vitamin D Status and SARS-CoV-2 Infection and COVID-19 Clinical Outcomes. *Front Public Health.* 2021 Dec 22;9:736665. doi:10.3389/fpubh.2021.736665